JPMorgan Chase & Co. Purchases 290,169 Shares of Ventyx Biosciences, Inc. $VTYX

JPMorgan Chase & Co. lifted its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 63.4% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 748,088 shares of the company’s stock after acquiring an additional 290,169 shares during the period. JPMorgan Chase & Co.’s holdings in Ventyx Biosciences were worth $2,327,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in VTYX. Hudson Bay Capital Management LP acquired a new stake in Ventyx Biosciences during the 2nd quarter valued at $34,000. Persistent Asset Partners Ltd acquired a new stake in Ventyx Biosciences during the 3rd quarter valued at $51,000. Engineers Gate Manager LP acquired a new stake in Ventyx Biosciences during the 2nd quarter valued at $42,000. Jacobs Levy Equity Management Inc. acquired a new stake in Ventyx Biosciences during the 3rd quarter valued at $61,000. Finally, Prelude Capital Management LLC lifted its holdings in Ventyx Biosciences by 35.0% during the 3rd quarter. Prelude Capital Management LLC now owns 21,200 shares of the company’s stock valued at $66,000 after purchasing an additional 5,500 shares during the last quarter. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Stock Performance

VTYX opened at $14.00 on Tuesday. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $25.00. The company has a market capitalization of $1.00 billion, a P/E ratio of -9.33 and a beta of 1.26. The stock has a fifty day moving average of $13.98 and a 200-day moving average of $10.20.

Analysts Set New Price Targets

VTYX has been the subject of several research reports. HC Wainwright downgraded Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 price target for the company. in a report on Thursday, January 8th. Wall Street Zen raised Ventyx Biosciences to a “hold” rating in a report on Saturday, March 7th. Lifesci Capital reaffirmed a “market perform” rating and set a $14.00 price target on shares of Ventyx Biosciences in a report on Thursday, January 8th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $14.00 price target on shares of Ventyx Biosciences in a report on Thursday, January 8th. Finally, Piper Sandler downgraded Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price target for the company. in a report on Thursday, January 8th. Eight analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $14.00.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.